Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37225706.
- Also identified by DOI 10.1038/s41467-023-38020-8 and PMC identifier 10209201.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Despite intensive research since the emergence of SARS-CoV-2, it has remained unclear precisely which components of the early immune response protect against the development of severe COVID-19. Here, we perform a comprehensive immunogenetic and virologic analysis of nasopharyngeal and peripheral blood samples obtained during the acute phase of infection with SARS-CoV-2. We find that soluble and transcriptional markers of systemic inflammation peak during the first week after symptom onset and correlate directly with upper airways viral loads (UA-VLs), whereas the contemporaneous frequencies of circulating viral nucleocapsid (NC)-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells correlate inversely with various inflammatory markers and UA-VLs. In addition, we show that high frequencies of activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells are present in acutely infected nasopharyngeal tissue, many of which express genes encoding various effector molecules, such as cytotoxic proteins and IFN-γ. The presence of IFNG mRNA-expressing CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the infected epithelium is further linked with common patterns of gene expression among virus-susceptible target cells and better local control of SARS-CoV-2. Collectively, these results identify an immune correlate of protection against SARS-CoV-2, which could inform the development of more effective vaccines to combat the acute and chronic illnesses attributable to COVID-19.
Medical subject headings
- Humans
- SARS-CoV-2
- CD8-Positive T-Lymphocytes
- Seroconversion
- COVID-19
- Nucleocapsid